{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:10:58Z","timestamp":1761894658543},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.ctrv.2007.12.005","type":"journal-article","created":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T13:39:57Z","timestamp":1201873197000},"page":"283-291","source":"Crossref","is-referenced-by-count":25,"title":["Lenalidomide: A new therapy for multiple myeloma"],"prefix":"10.1016","volume":"34","author":[{"given":"Antonio","family":"Palumbo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas San","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2007.12.005_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjc.6602774","article-title":"Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide","volume":"93","author":"Bartlett","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2007.12.005_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2004.1.237","article-title":"Multiple myeloma","author":"Harousseau","year":"2004","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2007.12.005_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-006-0239-5","article-title":"Towards a new age in the treatment of multiple myeloma","volume":"86","author":"Piazza","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2007.12.005_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ctrv.2007.12.005_bib5","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2122. Cancer-related fatigue. V.3.2007. Available from: <http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/fatigue.pdf> [accessed 26.09.07]."},{"key":"10.1016\/j.ctrv.2007.12.005_bib6","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ejca.2006.04.004","article-title":"Thalidomide and lenalidomide in the treatment of multiple myeloma","volume":"42","author":"Kumar","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2007.12.005_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14656566.8.4.497","article-title":"The evolving role of lenalidomide in the treatment of hematologic malignancies","volume":"8","author":"Kastritis","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ctrv.2007.12.005_bib8","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1586\/14737140.6.8.1165","article-title":"Lenalidomide in multiple myeloma","volume":"6","author":"Richardson","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2007.12.005_bib9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1586\/14737140.6.9.1239","article-title":"Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma","volume":"6","author":"Raje","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2007.12.005_bib10","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.12.005_bib11","article-title":"Lenalidomide and bortezomib inhibit osteoclast differentiation and activation in multiple myeloma: clinical implications","volume":"108","author":"Breitkreutz","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib12","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2007.12.005_bib13","first-page":"102","article-title":"Revlimid 25mg (REV 25)\u00d720 versus 50mg (REV 50)\u00d710 q 28days with bridging of 5mg\u00d710 versus 10mg\u00d75 as post-transplant salvage therapy for multiple myeloma (MM)","author":"Zangari","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.12.005_bib14","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.12.005_bib15","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"For the Multiple Myeloma-009 Study Investigators. Oral lenalidomide plus dexamethasone for relapsed\/refractory multiple myeloma","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.005_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"For the Multiple Myeloma-010 Study Investigators. Lenalidomide plus dexamethasone versus dexamethasone alone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2007.12.005_bib17","article-title":"Lenalidomide in combination with dexamethasone is more effective than dexamethasone at first relapse in relapsed multiple myeloma","volume":"108","author":"Stadtmauer","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib18","article-title":"Effect of Len\/Dex in MM despite Thal resistance","volume":"92","author":"Wang","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.12.005_bib19","article-title":"Lenalidomide in combination with dexamethasone was more effective than dexamethasone in patients who have received prior thalidomide for relapsed or refractory multiple myeloma","volume":"108","author":"Wang","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"10.1016\/j.ctrv.2007.12.005_bib20","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2007.12.005_bib21","volume":"108","author":"Weber","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib22","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.12.005_bib23","article-title":"Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial","volume":"108","author":"Bahlis","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib24","article-title":"Lenalidomide (L) in combination with dexamethasone (D) improves overall survival and time to progression in elderly patients (pts) with relapsed or refractory (rel\/ref) multiple myeloma (MM)","volume":"108","author":"Chanan-Khan","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib25","volume":"108","author":"Chanan-Khan","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib26","article-title":"Effect of Len\/Dex in MM in different age groups","volume":"92","author":"Lonial","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.12.005_bib27","article-title":"Lenalidomide (Revlimid\u00ae) +\/- corticosteroids in elderly patients with relapsed\/refractory multiple myeloma","volume":"108","author":"Reece","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib28","article-title":"Use of lenalidomide (Revlimid\u00ae) +\/- corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels","volume":"108","author":"Reece","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib29","article-title":"Lenalidomide induced myelosupression is potentially associated with renal dysfunction in treatment na\u0131\u00a8ve myeloma (MM) patients receiving BiRD (Biaxin\u00ae\/Revlimid\u00ae\/Dexamethasone) combination therapy (Rx)","volume":"108","author":"Niesvizky","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib30","first-page":"217","article-title":"Recommended management of cytopenia for len\/dex in MM","volume":"92","author":"Sonneveld","year":"2007","journal-title":"Haematologica\/Hematol J"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib31","first-page":"217","article-title":"Management of non-haematological toxicity of len\/dex","volume":"92","author":"Attal","year":"2007","journal-title":"Haematologica\/Hematol J"},{"key":"10.1016\/j.ctrv.2007.12.005_bib32","doi-asserted-by":"crossref","unstructured":"Niesvizky R, Spencer A, Wang M, et al. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin. ASCO Meeting Abstracts 2006;24. [Abstract 7506].","DOI":"10.1200\/jco.2006.24.18_suppl.7506"},{"key":"10.1016\/j.ctrv.2007.12.005_bib33","article-title":"High incidence of thrombotic events observed in patients receiving lenalidomide (L)+dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis","volume":"106","author":"Zonder","year":"2005","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib34","doi-asserted-by":"crossref","unstructured":"Bennett CL, Hussain Z, Courtney M, Yarnold P, Raisch D, McKoy JM. RADAR update on thalidomide (Thal)- and lenalidomide (Len)-associated venous thromboembolism (VTE): safety concerns persist for multiple myeloma (MM) despite FDA approvals in this setting. Blood (ASH Annual Meeting Abstracts) 2006;108 [Abstract 3310].","DOI":"10.1182\/blood.V108.11.3310.3310"},{"key":"10.1016\/j.ctrv.2007.12.005_bib35","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, Abonour R, Siegel D, Greipp P. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASCO Annual Meeting Proceedings 2007;25(18S) [Abstract LBA8025].","DOI":"10.1200\/jco.2008.26.15_suppl.8504"},{"key":"10.1016\/j.ctrv.2007.12.005_bib36","doi-asserted-by":"crossref","unstructured":"Durie BG, Richardson P, Palumbo A, et al. Deep vein thrombosis in myeloma: estimate of prevalence and recommendations for therapy based upon a survey of members of the International Myeloma Working Group (IMWG). Blood (ASH Annual Meeting Abstracts) 2006;108 [Abstract 3571].","DOI":"10.1182\/blood.V108.11.3571.3571"},{"key":"10.1016\/j.ctrv.2007.12.005_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2006.1.348","article-title":"Thrombotic complications of myeloma therapy","author":"Zonder","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2007.12.005_bib38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/asheducation-2005.1.458","article-title":"Acquired risk factors for venous thromboembolism in medical patients","author":"Prandoni","year":"2005","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2007.12.005_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1378\/chest.06-2360","article-title":"Risk of thrombosis with lenalidomide and its prevention with aspirin","volume":"131","author":"Hirsh","year":"2007","journal-title":"Chest"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib40","first-page":"217","article-title":"VTE management recommendations for len\/dex in MM","volume":"92","author":"Palumbo","year":"2007","journal-title":"Haematologica\/Hematol J"},{"key":"10.1016\/j.ctrv.2007.12.005_bib41","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib42","article-title":"RAD (Revlimid, Adriamycin, Dex) is a new treatment regimen for relapsed multiple myeloma","volume":"92","author":"Knop","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.12.005_bib43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1365-2141.2007.06538.x","article-title":"Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients","volume":"137","author":"Morgan","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2007.12.005_bib44","article-title":"Lenalidomide plus bortezomib (Rev-Vel) in relapsed and\/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib45","article-title":"Phase 2 study of Rev\/Vel\/Dex in relapsed\/refractory MM","volume":"92","author":"Richardson","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.12.005_bib46","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","article-title":"Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma","volume":"82","author":"Lacy","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ctrv.2007.12.005_bib47","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.12.005_bib48","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"issue":"s2","key":"10.1016\/j.ctrv.2007.12.005_bib49","article-title":"BiRD (Biaxin\u00ae\/Revlimid\u00ae\/Dexamethasone) in myeloma (MM)","volume":"92","author":"Niesvizky","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2007.12.005_bib50","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2007.12.005_bib51","article-title":"Melphalan (M), prednisone (P) and lenalidomide (R) combination (MPR) for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation","volume":"108","author":"Vivek","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib52","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2007.12.005_bib53","article-title":"Cardiac biomarkers predict for ability to tolerate and complete therapy with lenalidomide \u00b1 dexamethasone in AL amyloidosis","volume":"108","author":"Dispenzieri","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2007.12.005_bib54","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737207001910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T11:33:26Z","timestamp":1588332806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737207001910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0305737207001910"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2007.12.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}